Vazoaktif Ve İnotropik Ajanlar

Hensyl WR (ed).Stedman's medical Dictionary.25 th ed.Baltimore :Williams and Wilkins, 1990.

Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004; 32:1928-48

Tabaee A, Givertz MM. Pharmacologic management of the hypotensive patient. In: Irwin RS, Rippe JM (eds). Intensive Care Medicine .5 th ed. Philadelphia: Lippincott Williams and Wilkins, 2003:295-301

Kellum JA, Decker JM. Use of dopamine in acute renal failure : A meta-analysis. Crit Care Med 2001;29:1526-31

Marik PE. Low-dose dopamin: A systematic review. İntensive Care Med 2002; 28:877-83

Argalious M, Motta P, Khandwala F, et al. 'Renal dose ' dopamine is associated with the risk of new onset atrial fibrillation after cardiac surgery. Crit Care Med 2005;33:1327-32

Al-Hesayen A, Azevedo ER, Newton GE, et al. The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure.J Am Coll Cardiol 2002; 39: 1269

Nolan JP, Deakin CD, Soar J, et al. European resuscitation council guidelines for resuscitation 2005. Section 4. Adult advanced life support . Resuscitation 2005; 67(Suppl 1): 39-86

Soar J, Deakin CD, Nolan JP, et al. European resuscitation council guidelines for resuscitation 2005.Section 7 .Cardiac arrest in special circumstances. Resuscitation 2005;67 (Suppl 1) : 135-70

Trager K, De Backer D, Radermacher P. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 2003;9:271-8.

De Backer D, Creteur J, Silva E, et al. Effects od dopamine, norepinephrine and epinephrine on the splanchnic circulation in septic shock:which is best? Crit Care Med 2003; 31:1659

Bellomo R. Noradrenalin: Friend or foe? Heart,Lung and Circulation 2003;12:42-8

Hernandez G, Brunn A, Romero C, et al. Management of septic shock with a norepinephrine - based haemodynamic algorthim. Resuscitation 2006; 66:63-9.

Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care Med 1991;19:1395

Holmes CL. Vasoactive drugs in the intensive care unit. Curr Opin Crit Care 2005;11:413-17

Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 2003;31:946-55

Löllgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med 1990;18:S56

Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004;32:1327

Leather HA,Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002;30:2548

Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock ? Chest 1993;103:1826

Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993;19:151

Ulusoy, H., Şenel, H., Küçük, O. (2019) Yoğun Bakımda Vazopresör ve İnotrop Tedavisi. Nimet Şenoğlu (Ed.), Olgularla Yoğun Bakım Protokolleri (s. 233-241). Ankara :Nobel Tıp Kitabevleri Ltd. Şti ISBN:978-605-7578-04-4